Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Auto stocks lead among gainers
Wed, 29 Oct 11:30 am

After opening firm, the Indian indices have continued to witness buying momentum. The buying interest is highest in auto, oil and gas and FMCG stocks. Only stocks form power sector are trading in red today.

The BSE-Sensex is trading up 161 points. The NSE-Nifty is trading up 42 points. Both, BSE Mid Cap index is trading up 0.6% and BSE Small Cap index is trading up 0.7%. The rupee is trading at 61.35 to the US dollar.

Most software stocks are trading higher today. Infosys and HCL Technologies are leading the gainers. As per a leading financial daily, India's second largest software firm Infosys, is ready to make large acquisitions to drive growth. Chief Operating Officer (COO), U.B. Pravin Rao has stated that the company would consider acquiring companies in the US$ 600-700 m range. Also, the company was open to even larger acquisitions as long as it is in line with the company's long term strategy. CEO Vishal Sikka had stated earlier that Infosys would consider acquiring those firms that offer a strategic advantage in terms of domain knowledge time-to-market capability and geography. Infosys has been extremely conservative in the past regarding acquisitions and has acquired only 5 companies since inception. As on 30 September 2014, the company had cash and cash equivalents of nearly US$ 5.5 bn. Infosys was trading up 1.3% at the time of writing.

Indian pharma stocks are trading mixed with Dishman pharma and Wockhardt Ltd being the leading gainers in the pack, while Biocon Ltd and Ipca are the leading losers. As per the financial daily, Dr Reddy's Laboratories has launched Sirolumus in the US market. The company has launched 1mg and 2mg strength tablets in US followed by the USFDA approval. The drug is generic equivalent to Rapamune, used prevention of organ rejection in kidney transplant patients. Reportedly, the Rapamune tablets brand had US sales of approximately US$ 206 m for the twelve months ending in August 2014 according to IMS Health. This will be an lucrative opportunity for Dr Reddy's since its a low competition opportunity. Dr Reddys is trading down by 0.2%

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto stocks lead among gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.